The Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has submitted a Form 8.3 disclosure regarding its interest in Avadel Pharmaceuticals plc. As of January 23, 2026, Vanguard controls 5,861,826 ordinary shares, representing 6.02% of Avadel's stock. This disclosure is part of regulatory requirements under Rule 8.3 of the Irish Takeover Panel Act, 1997, which applies to entities holding a 1% or greater interest in a company.

Recent trading activity includes the purchase of 762 shares at $21.50 per unit and the sale of 288 shares at the same price. No dealings involving cash-settled derivatives were reported. Vanguard has not engaged in any indemnity or other dealing arrangements related to Avadel shares.